Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan · Delayed Price · Currency is TWD 124.00
-6.00 (-4.62%)
Sep 24, 2026, 1:30 PM CST
Handa Pharmaceuticals Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20,154 | 13,530 | 10,576 | 25,891 | 16,074 | 8,451 | |
Market Cap Growth | 8.43% | 27.93% | -59.15% | 61.07% | 90.20% | 199.72% |
Enterprise Value | 16,467 | 10,965 | 8,085 | 23,747 | 15,869 | 8,249 |
Last Close Price | 124.00 | 84.26 | 72.09 | 175.38 | 116.21 | 64.53 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.08 | 18.05 | 22.37 | 35.62 | - | - |
Forward PE | 25.67 | 5.59 | 5.59 | 14.69 | - | - |
PS Ratio | 16.64 | 7.82 | 12.73 | 23.40 | 81.32 | 289.08 |
PB Ratio | 4.01 | 2.39 | 3.39 | 9.39 | 22.29 | 18.25 |
P/TBV Ratio | 4.66 | 2.77 | 4.89 | 9.52 | 23.46 | 19.80 |
P/FCF Ratio | 31.82 | 59.68 | 21.59 | 38.79 | - | - |
P/OCF Ratio | 30.44 | 55.54 | 21.25 | 38.74 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.60 | 6.34 | 9.73 | 21.47 | 80.28 | 282.15 |
EV/EBITDA Ratio | 26.70 | 10.10 | 19.20 | 34.00 | - | - |
EV/EBIT Ratio | 36.39 | 11.74 | 19.34 | 34.25 | - | - |
EV/FCF Ratio | 26.00 | 48.36 | 16.51 | 35.58 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.03 |
Debt / EBITDA Ratio | 0.07 | 0.04 | 0.09 | 0.02 | - | - |
Debt / FCF Ratio | 0.07 | 0.21 | 0.08 | 0.02 | - | - |
Net Debt / Equity Ratio | -0.73 | -0.65 | -0.57 | -0.84 | -0.47 | -0.59 |
Net Debt / EBITDA Ratio | -6.09 | -3.37 | -4.25 | -3.30 | 4.14 | 1.11 |
Net Debt / FCF Ratio | -5.82 | -16.13 | -3.65 | -3.45 | 1.59 | 1.47 |
Asset Turnover | 0.24 | 0.37 | 0.26 | 0.58 | 0.31 | 0.05 |
Quick Ratio | 8.88 | 36.41 | 8.49 | 12.89 | 11.63 | 10.05 |
Current Ratio | 8.98 | 36.60 | 8.72 | 12.96 | 13.07 | 10.57 |
Return on Equity (ROE) | 10.60% | 17.08% | 16.10% | 41.81% | -6.76% | -49.43% |
Return on Assets (ROA) | 5.53% | 12.51% | 8.07% | 22.64% | -8.54% | -29.36% |
Return on Invested Capital (ROIC) | 24.98% | 44.86% | 46.33% | 151.89% | -30.57% | -118.36% |
Return on Capital Employed (ROCE) | 8.90% | 16.20% | 13.10% | 24.50% | -11.80% | -54.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.43% | 5.54% | 4.47% | 2.81% | -0.25% | -2.93% |
FCF Yield | 3.14% | 1.68% | 4.63% | 2.58% | -1.32% | -2.19% |
Dividend Yield | 1.61% | 2.37% | 2.09% | 0.57% | - | - |
Payout Ratio | 48.20% | 31.52% | 29.84% | - | - | - |
Buyback Yield / Dilution | -10.81% | -10.09% | -4.73% | -7.29% | -6.65% | -1.87% |
Total Shareholder Return | -9.20% | -7.71% | -2.64% | -6.72% | -6.65% | -1.87% |